|
Pure
Bioscience ~ $6,500,000 Common Stock ~ March 2006
PURE Biosciences patented new
antimicrobial molecule, silver dihydrogen citrate (SDC), is
stabilized ionic silver that can serve as a platform for a broad
range of products in various markets. The Company is pursuing
near-term revenue opportunities for its first commercialized SDC-based
product, Axen30, a powerful hard surface disinfectant, while
developing large mid- and long-term revenue opportunities in
active ingredient and pharmaceutical products. Taglich Brothers
was pleased to provide the Company the financial resources
needed to significantly accelerate their business strategy.
The information
contained herein does not constitute a solicitation of any order
to buy or sell any securities. The information provided herein
may be displayed and printed for your personal, noncommercial
use only. You may not reproduce, retransmit, distribute,
disseminate, sell, publish, broadcast or circulate the
information to anyone, without the express written consent of
Taglich Brothers, Inc.
|
